Previous 10 | Next 10 |
- 73 Ambulatory DMD Patients Enrolled - - Topline Data Anticipated 2H:2023 - SAN FRANCISCO, June 08, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced completion of patient enrollment for LELANTOS-2, a Phase 3 clinical study of pamrevlumab in patients...
SAN FRANCISCO, May 26, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 9 at 1:30pm EDT. A live audio webcast of the event...
Do You Have These Top Biotech Stocks On Your Watchlist? Depending on your investment appetite, the stock market offers various types of opportunities. Biotech stocks have a reputation for being a high-risk, high-reward sector to invest in. This is an industry that includes compa...
FIBROGEN INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of FibroGen, Inc. - FGEN FIBROGEN INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Contin...
Shares of FibroGen (NASDAQ:FGEN) have added 25.3% to $9.95 in Tuesday afternoon trading, after the biopharmaceutical company posted Q1 2022 earnings that beat estimates and raised its 2022 ending cash balance guidance. FGEN's Q1 GAAP EPS of -$0.68 beat estimates by $0.24, and r...
FibroGen, Inc. (FGEN) Q1 2022 Earnings Conference Call May 09, 2022 5:00 PM ET Company Participants Michael Tung – Corporate Strategy/Investor Relations Enrique Conterno – Chief Executive Officer Mark Eisner – Chief Medical Officer Juan Graham – Chief Financial Off...
FibroGen press release (NASDAQ:FGEN): Q1 GAAP EPS of -$0.68 beats by $0.24. Revenue of $60.8M (+58.2% Y/Y) beats by $32.04M. Based on our latest forecast, we estimate a 2022 ending cash balance of $310-340 million. For further details see: FibroGen GAAP EPS of -$0.68 beats by $0.24, rev...
Completed enrollment in ZEPHYRUS-1 Phase 3 study of pamrevlumab in idiopathic pulmonary fibrosis 1Q 2022 revenue of $60.8M, growth of 58% vs. 1Q 2021 Significant roxadustat volume growth in China in first quarter 2022 offsetting NRDL price reduction S...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips We’re starting off another week of trading with an overview of the biggest pre-market stock mover for Monday! Source: Eric Urquhart/Shutterstock.com News moving stocks this morning include clinical trial resu...
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into FibroGen, Inc. (NasdaqGS: FGEN). On April 6, 2021, the Company disclosed that cardiova...
News, Short Squeeze, Breakout and More Instantly...
Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the J.P. Morgan Re...
FibroGen Inc (NASDAQ:FGEN) announced topline data from the Fortis Therapeutics-sponsored Phase 1 study of FG-3246 (also known as FOR46), a pot...
FG-3246 demonstrated efficacy in adenocarcinoma selected cohorts receiving biologically active doses of FG-3246 at ≥ 1.2 mg/kg in heavily pre-treated, biomarker unselected patients: Median radiographic progression free survival of 8.7 months PSA50 response in 36% ...